Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed last Friday at ...

Iovance Biotherapeutics recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its 2024 earnings ...

IOVA has been the subject of several other reports. Robert W. Baird dropped their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a price target of $22.00. The company’s shares closed ...

Shares of NASDAQ:IOVA opened at $4.04 on Monday. The firm has a market cap of $1.23 billion, a PE ratio of -2.71 and a beta of 0.53. The firm’s 50 day simple moving average is $6.21 and its 200 ...

Iovance Biotherapeutics, Inc. IOVA incurred a fourth-quarter 2024 loss of 26 cents per share, narrower than the Zacks Consensus Estimate of a loss of 27 cents. In the year-ago quarter, the company ...

Iovance Biotherapeutics Inc (NASDAQ:IOVA) achieved the upper end of their 2024 revenue guidance, with total product revenue of $164.1 million. The company has a robust manufacturing network with a ...

The market expects Iovance Biotherapeutics (IOVA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...